Robert W. Baird initiated coverage on PROCEPT BioRobotics with a new price target
$PRCT
Medical/Dental Instruments
Health Care
Robert W. Baird initiated coverage of PROCEPT BioRobotics with a rating of Neutral and set a new price target of $30.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/6/2026 | $25.00 | Buy → Hold | Truist |
| 6/24/2026 | $30.00 | Outperform | Evercore ISI |
| 6/11/2026 | $29.00 | Outperform → Market Perform | Leerink Partners |
| 3/6/2026 | $30.00 | Neutral | Robert W. Baird |
| 2/26/2026 | Outperform → Perform | Oppenheimer | |
| 2/26/2026 | $20.00 | Neutral → Underperform | BofA Securities |
| 12/12/2025 | $62.00 | Buy | UBS |
| 12/8/2025 | $38.00 | Buy → Neutral | BofA Securities |
8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)
SD - PROCEPT BioRobotics Corp (0001588978) (Filer)
SCHEDULE 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
Truist downgraded PROCEPT BioRobotics from Buy to Hold and set a new price target of $25.00
Evercore ISI initiated coverage of PROCEPT BioRobotics with a rating of Outperform and set a new price target of $30.00
Leerink Partners downgraded PROCEPT BioRobotics from Outperform to Market Perform and set a new price target of $29.00
AUSTIN, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (NASDAQ:MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the appointment of Reza Zadno, Ph.D., to the Board as an independent director, effective July 14, 2026. Dr. Zadno will also serve as a member of the Compensation Committee. "We are pleased to welcome Reza to the Mobia Medical Board of Directors," said Richard Foust, President and Chief Executive Officer of Mobia Medical. "He has built and scaled multiple public medical technology companies, and his operational perspective and public company governance experience wi
SAN JOSE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2026 after market close on Tuesday, August 4, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/8fznodv2 Dial-in registration for sell-side research ana
SAN JOSE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the randomized WATER IV study evaluating Aquablation® therapy versus radical prostatectomy, and FDA Investigational Device Exemption (IDE) approval for a second randomized protocol evaluating Aquablation therapy versus active surveillance. The first randomized WATER IV study (WATER IV RP) fully enrolled 280 planned patients and is the only FDA randomized study comparing Aquablation therapy to radical prostatectomy, the established surgical standard of care. Based on current timelines, the Company e
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
AUSTIN, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (NASDAQ:MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the appointment of Reza Zadno, Ph.D., to the Board as an independent director, effective July 14, 2026. Dr. Zadno will also serve as a member of the Compensation Committee. "We are pleased to welcome Reza to the Mobia Medical Board of Directors," said Richard Foust, President and Chief Executive Officer of Mobia Medical. "He has built and scaled multiple public medical technology companies, and his operational perspective and public company governance experience wi
SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th
Carl J. St. Bernard Appointed as Chief Executive Officer Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions, announced today that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a key participant in the round that included participation from multiple strategic investors. The funding will be used to support the company's upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology. "For decades, the
SAN JOSE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2026 after market close on Tuesday, August 4, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/8fznodv2 Dial-in registration for sell-side research ana
SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2026. "Over the past six months, we have taken decisive actions to reset the organization by sharpening our focus on operational excellence, accountability, and commercial discipline, and our first quarter results reflect the early impact of that work," said Larry Wood, Chief Executive Officer. "We delivered $83.1 million in revenue, driven by strong U.S. system sales and improved pricing.
SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2026 after market close on Wednesday, April 29, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/rdtftqik/ Dial-in registration for sell-side research
SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)